SG Americas Securities LLC Buys Shares of 425,096 C4 Therapeutics, Inc. (NASDAQ:CCCC)

SG Americas Securities LLC bought a new stake in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 425,096 shares of the company's stock, valued at approximately $680,000. SG Americas Securities LLC owned about 0.60% of C4 Therapeutics at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Jane Street Group LLC raised its holdings in shares of C4 Therapeutics by 49.4% during the fourth quarter. Jane Street Group LLC now owns 152,774 shares of the company's stock valued at $550,000 after acquiring an additional 50,523 shares during the last quarter. Millennium Management LLC raised its holdings in shares of C4 Therapeutics by 1,548.3% during the fourth quarter. Millennium Management LLC now owns 360,125 shares of the company's stock valued at $1,296,000 after acquiring an additional 338,277 shares during the last quarter. Nuveen Asset Management LLC raised its holdings in shares of C4 Therapeutics by 6.4% during the fourth quarter. Nuveen Asset Management LLC now owns 192,424 shares of the company's stock valued at $693,000 after acquiring an additional 11,571 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of C4 Therapeutics by 4.6% during the fourth quarter. Rhumbline Advisers now owns 100,015 shares of the company's stock valued at $360,000 after acquiring an additional 4,366 shares during the last quarter. Finally, Sei Investments Co. acquired a new position in shares of C4 Therapeutics during the fourth quarter valued at approximately $45,000. Institutional investors and hedge funds own 78.81% of the company's stock.

C4 Therapeutics Stock Performance

NASDAQ:CCCC opened at $1.42 on Friday. C4 Therapeutics, Inc. has a one year low of $1.09 and a one year high of $7.66. The stock has a market cap of $100.83 million, a PE ratio of -0.97 and a beta of 2.93. The stock has a 50 day moving average price of $1.47 and a 200 day moving average price of $2.50.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.11. C4 Therapeutics had a negative return on equity of 45.86% and a negative net margin of 259.60%. The firm had revenue of $7.20 million during the quarter, compared to analysts' expectations of $3.54 million. As a group, analysts predict that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.

Want to see what other hedge funds are holding CCCC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.